Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation

Oncogene

Volumn 31, Issue 3, 2012, Pages 390-401

  Mathiasen, D P ^a   Egebjerg, C ^a   Andersen, S H ^a   Rafn, B ^a   Puustinen, P ^a   Khanna, A ^b   Daugaard, M ^a   Valo, E ^c   Tuomela, S ^d   Bottzauw T ^a   Nielsen, C F ^a   Willumsen, B M ^e   Hautaniemi, S ^c   Lahesmaa, R ^d   Westermarck, J ^d   Jaattela M ^a   Kallunki, T ^a  

^a Institute of Cancer Biology   (Denmark)

^b UNIVERSITY OF TAMPERE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ATF3; c Myc; CIP2A; JNK knockout; Ras transformation

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 9; ONCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; RAS PROTEIN; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DOWN REGULATION; FIBROBLAST; GENOTYPE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROBLASTS; GENES, RAS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 9; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS;

MURINAE;

EID: 84855913352     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.230     Document Type: Article

References (65)

1. Alarcon-Vargas D, Ronai Z. (2004). c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J Biol Chem 279: 5008-5016. (Pubitemid 38199097)
2. Amati B, Frank SR, Donjerkovic D, Taubert S. (2001). Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim Biophys Acta 1471: M135-M145. (Pubitemid 32206689)
3. Behrens A, Jochum W, Sibilia M, Wagner EF. (2000). Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 19: 2657-2663. (Pubitemid 30326415)
4. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z et al. (2003). Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63: 8103-8107. (Pubitemid 37549453)
5. Bhoumik A, Gangi L, Ronai Z. (2004). Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 64: 8222-8230. (Pubitemid 39491759)
6. Bhoumik A, Ronai Z. (2008). ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 7: 2341-2345.
7. Binetruy B, Smeal T, Karin M. (1991). Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature 351: 122-127. (Pubitemid 21896543)
8. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. (1999). The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 19: 1938-1949. (Pubitemid 29098252)
9. Brunet A, Pages G, Pouyssegur J. (1994). Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 9: 3379-3387. (Pubitemid 24338470)
10. Cai Y, Zhang C, Naea T, Aso T, Tanaka M, Oshiro S et al. (2000). Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH2-terminal kinase and promoter response element. Blood 96: 2140-2148.
11. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L et al. (2001). Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 61: 3908-3912. (Pubitemid 32720949)
12. Ciardiello F, Valverius EM, Colucci-D'Amato GL, Kim N, Bassin RH, Salomon DS. (1990). Differential growth factor expression in transformed mouse NIH-3T3 cells. J Cell Biochem 42: 45-57. (Pubitemid 20034293)
13. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X et al. (2009). CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15: 5092-5100.
14. Cowley S, Paterson H, Kemp P, Marshall CJ. (1994). Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852. (Pubitemid 24187682)
15. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T et al. (1994). JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037. (Pubitemid 24106383)
16. Dietrich N, Thastrup J, Holmberg C, Gyrd-Hansen M, Fehrenbacher N, Lademann U et al. (2004). JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways. Cell Death Differ 11: 301-313. (Pubitemid 38313139)
17. Eilers M, Eisenman RN. (2008). Myc's broad reach. Genes Dev 22: 2755-2766.
18. Fuchs SY, Tappin I, Ronai Z. (2000). Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 275: 12560-12564. (Pubitemid 30241402)
19. Furth ME, Davis LJ, Fleurdelys B, Scolnick EM. (1982). Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus of the cellular ras gene family. J Virol 43: 294-304. (Pubitemid 12084907)
20. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V et al. (2006). Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8: 764-770.
21. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Dé rijard B et al. (1996). Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15: 2760-2770. (Pubitemid 26176253)
22. Gupta S, Campbell D, Derijard B, Davis RJ. (1995). Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393.
23. Hibi M, Lin A, Smeal T, Minden A, Karin M. (1993). Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7: 2135-2148. (Pubitemid 23336140)
24. Hubbard TJ, Aken BL, Ayling S, Ballester B, Beal K, Bragin E et al. (2009). Ensembl 2009. Nucleic Acids Res 37: D690-D697.
25. Jacobsen K, Groth A, Willumsen BM. (2002). Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation. Oncogene 21: 3058-3067. (Pubitemid 34522906)
26. Johnson R, Spiegelman B, Hanahan D, Wisdom R. (1996). Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16: 4504-4511. (Pubitemid 26251252)
27. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T et al. (2007). CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62. (Pubitemid 47039258)
28. Kallunki T, Su B, Tsigelny I, Sluss HK, Derijard B, Moore G et al. (1994). JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 8: 2996-3007.
29. Kawagishi J, Kumabe T, Yoshimoto T, Yamamoto T. (1995). Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30: 224-232.
30. Kawasaki H, Schiltz L, Chiu R, Itakura K, Taira K, Nakatani Y et al. (2000). ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature 405: 195-200. (Pubitemid 30313539)
31. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, de Marval PM et al. (2010). The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 70: 3080-3088.
32. Kemp CJ. (2005). Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 15: 460-473. (Pubitemid 41318046)
33. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M et al. (2009). MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101: 793-805.
34. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L et al. (1996). Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16: 3923-3933.
35. Kolch W, Heidecker G, Lloyd P, Rapp UR. (1991). Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349: 426-428. (Pubitemid 21926105)
36. Krautwald S, Büscher D, Kummer V, Buder S, Baccarini M. (1996). Involvement of the protein tyrosine phosphatase SHP-1 in Ras-mediated activation of the mitogen-activated protein kinase pathway. Mol Cell Biol 16: 5955-5963. (Pubitemid 26360955)
37. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF et al. (1994). The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160. (Pubitemid 24153440)
38. Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA. (1986). Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 6: 1917-1925.
39. Livingstone C, Patel G, Jones N. (1995). ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J 14: 1785-1797.
40. Lopez-Bergami P, Kim H, Dewing A, Goydos J, Aaronson S, Ronai Z. (2010). c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem 285: 903-913.
41. Malumbres M, Barbacid M. (2003). RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465. (Pubitemid 37328850)
42. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K et al. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970. (Pubitemid 24281496)
43. Martinato F, Cesaroni M, Amati B, Guccione E. (2008). Analysis of Myc-induced histone modifications on target chromatin. PLoS One 3: e3650.
44. Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C et al. (2008). Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience 151: 771-779.
45. Nielsen C, Thastrup J, Bottzauw T, Jaattela M, Kallunki T. (2007). c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1. Cancer Res 67: 178-185. (Pubitemid 46142773)
46. Nielsen KH, Gredsted L, Broach JR, Willumsen BM. (2001). Sensitivity of wild type and mutant ras alleles to Ras specific exchange factors: identification of factor specific requirements. Oncogene 20: 2091-2100. (Pubitemid 32424003)
47. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. (1999). Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 274: 32580-32587. (Pubitemid 129535283)
48. Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomäki V et al. (2010). Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med 2: 65.
49. Pearn L, Fisher J, Burnett AK, Darley RL. (2007). The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 109: 4461-4469. (Pubitemid 46743416)
50. Perez S, Vial E, van Dam H, Castellazzi M. (2001). Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation. Oncogene 20: 1135-1141. (Pubitemid 32238863)
51. Potapova O, Gorospe M, Bost F, Dean NM, Gaarde WA, Mercola D et al. (2000). c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 275: 24767-24775. (Pubitemid 30626580)
52. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ et al. (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270: 7420-7426.
53. Schimanski CC, Zimmermann T, Schmidtmann I, Gockel I, Lang H, Galle PR et al. (2010). K-Ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. Int J Colorectal Dis 25: 181-186.
54. Sears R, Leone G, DeGregori J, Nevins JR. (1999). Ras enhances Myc protein stability. Mol Cell 3: 169-179. (Pubitemid 29292618)
55. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514.
56. Sharma A, Luke CT, Dower NA, Stone JC, Lorenzo PS. (2010). RasGRP1 is essential for ras activation by the tumor promoter 12-O-tetradecanoylphorbol-13- acetate in epidermal keratinocytes. J Biol Chem 285: 15724-15730.
57. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. (1991). Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354: 494-496. (Pubitemid 21896867)
58. Tamura K, Hua B, Adachi S, Guney I, Kawauchi J, Morioka M et al. (2005). Stress response gene ATF3 is a target of c-myc in seruminduced cell proliferation. EMBO J 24: 2590-2601. (Pubitemid 41076315)
59. Teruel T, Valverde AM, Navarro P, Benito M, Lorenzo M. (1998). Inhibition of PI 3-kinase and RAS blocks IGF-I and insulininduced uncoupling protein 1 gene expression in brown adipocytes. J Cell Physiol 176: 99-109. (Pubitemid 28277200)
60. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874. (Pubitemid 30257738)
61. Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P et al. (1994). Mitogen-activated protein kinase/extracellular signalregulated protein kinase activation by oncogenes, serum, and 12-Otetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem 269: 7030-7035.
62. Wang A, Arantes S, Yan L, Kiguchi K, McArthur MJ, Sahin A et al. (2008). The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. BMC Cancer 8: 268.
63. Yao D, Brownlee M. (2010). Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59: 249-255.
64. Yin X, Dewille JW, Hai T. (2008). A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27: 2118-2127. (Pubitemid 351483383)
65. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. (2003). An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69.